New treatments are needed in recurrent GBM since median survival with surgery, radiation, and temozolamide (TMZ) is only 14-20 months.

LMP744 is a novel non-camptothecin Top-1 and cMYC agent which has been extensively studied by the NCI in pre-clinical and phase I studies in solid tumors and lymphomas.

When Gibson Oncology discovered that LMP744 easily crossed the blood-brain barrier (BBB), the NIH initiated extensive pre-clinical studies on GBM and other brain tumors.

Those studies resulted in the NINDS receiving FDA approval to initiate a Phase II clinical trial in recurrent GBM.

The current market size for GBM drugs is estimated at $900 million in 2024 and is expected to grow to several billion dollars by 2031.

Data on the BBB transmission on the preclinical studies and on the design of the phase II trial can be obtained under confidentiality (CDA) by contacting Gibson Oncology.

Additionally…

Another Gibson drug, LMP400 also easily crosses the BBB and has very prolonged brain levels for over 24 hours.

NIH studies have shown low-dose LMP400 + niraparib is effective in animal models of PTEN-deficient brain tumors.

LMP400 also works by itself, and a higher dose, already known to be acceptable in clinical trials, likely would work even better.

LMP400 has also been shown at the Brain Cancer Center at Duke University to inhibit the growth of IDH-mutant astrocytoma in animal models. 

 Gibson Oncology Intellectual Property (1)

• U.S. and international patents on composition of matter.

• New Composition of Matter patents filed.

 Gibson Oncology Intellectual Property (2)

• Second Generation Compounds (AZA Indenos) have U.S. and International patents filed with oral drug administration possible.

• Protection with FDA ODD designation for LMP744 and LMP400.

Click here to return to the homepage.